Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry

Anderson, 1998, Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project, Ann Oncol, 9, 717, 10.1023/A:1008265532487 Hiddemann, 2014, How we manage follicular lymphoma, Leukemia, 28, 1388, 10.1038/leu.2014.91 Salles, 2011, Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial, Lancet, 377, 42, 10.1016/S0140-6736(10)62175-7 Relander, 2010, Prognostic factors in follicular lymphoma, J Clin Oncol, 28, 2902, 10.1200/JCO.2009.26.1693 Solal-Celigny, 2004, Follicular lymphoma international prognostic index, Blood, 104, 1258, 10.1182/blood-2003-12-4434 Buske, 2006, Blood, 108, 1504, 10.1182/blood-2006-01-013367 Kridel, 2012, Pathogenesis of follicular lymphoma, J Clin Invest, 122, 3424, 10.1172/JCI63186 Hiddemann, 2005, Blood, 106, 3725, 10.1182/blood-2005-01-0016 Odejide, 2014, A targeted mutational landscape of angioimmunoblastic T-cell lymphoma, Blood, 123, 1293, 10.1182/blood-2013-10-531509 Pott, 2012, MRD detection in B-cell non-Hodgkin lymphomas using Ig gene rearrangements and chromosomal translocations as targets for real-time quantitative PCR, 175 Lawrence, 2014, Discovery and saturation analysis of cancer genes across 21 tumour types, Nature, 505, 495, 10.1038/nature12912 Lawrence, 2014, Mutational heterogeneity in cancer and the search for new cancer-associated genes, Nature, 499, 214, 10.1038/nature12213 Reva, 2011, Predicting the functional impact of protein mutations: application to cancer genomics, Nucleic Acids Res, 39, e118, 10.1093/nar/gkr407 Bejar, 2011, Clinical effect of point mutations in myelodysplastic syndromes, N Engl J Med, 364, 2496, 10.1056/NEJMoa1013343 Leonard, 1991, The identification of discrete prognostic groups in low grade non-Hodgkin's lymphoma. The Scotland and Newcastle Lymphoma Group Therapy Working Party, Ann Oncol, 2, 655, 10.1093/oxfordjournals.annonc.a058044 Lopez-Guillermo, 1994, Applicability of the International Index for aggressive lymphomas to patients with low-grade lymphoma, J Clin Oncol, 12, 1343, 10.1200/JCO.1994.12.7.1343 Federico, 2009, Follicular Lymphoma International Prognostic Index 2: a new prognostic index for follicular lymphoma developed by the International Follicular Lymphoma Prognostic Factor Project, J Clin Oncol, 27, 4555, 10.1200/JCO.2008.21.3991 Smith, 2013, Dissecting follicular lymphoma: high versus low risk, Hematology Am Soc Hematol Educ Program, 2013, 561, 10.1182/asheducation-2013.1.561 Robins, 2000, Correcting for noncompliance and dependent censoring in an AIDS Clinical Trial with inverse probability of censoring weighted (IPCW) log-rank tests, Biometrics, 56, 779, 10.1111/j.0006-341X.2000.00779.x Yap, 2011, Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation, Blood, 117, 2451, 10.1182/blood-2010-11-321208 McCabe, 2012, Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27), Proc Natl Acad Sci USA, 109, 2989, 10.1073/pnas.1116418109 Lenz, 2008, Oncogenic CARD11 mutations in human diffuse large B cell lymphoma, Science, 319, 1676, 10.1126/science.1153629 Hunter, 2014, The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis, Blood, 123, 1637, 10.1182/blood-2013-09-525808 Trinh, 2013, Analysis of FOXO1 mutations in diffuse large B-cell lymphoma, Blood, 121, 3666, 10.1182/blood-2013-01-479865 Yildiz, 2015, Activating STAT6 mutations in follicular lymphoma, Blood, 125, 668, 10.1182/blood-2014-06-582650 Ying, 2013, MEF2B mutations lead to deregulated expression of the oncogene BCL6 in diffuse large B cell lymphoma, Nat Immunol, 14, 1084, 10.1038/ni.2688 Khodabakhshi, 2012, Recurrent targets of aberrant somatic hypermutation in lymphoma, Oncotarget, 3, 1308, 10.18632/oncotarget.653 Leich, 2009, Follicular lymphomas with and without translocation t(14;18) differ in gene expression profiles and genetic alterations, Blood, 114, 826, 10.1182/blood-2009-01-198580 Bödör, 2013, EZH2 mutations are frequent and represent an early event in follicular lymphoma, Blood, 122, 3165, 10.1182/blood-2013-04-496893 O'Shea, 2008, The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival, Blood, 112, 3126, 10.1182/blood-2008-05-154013 Cheung, 2010, Acquired TNFRSF14 mutations in follicular lymphoma are associated with worse prognosis, Cancer Res, 70, 9166, 10.1158/0008-5472.CAN-10-2460 Launay, 2012, High rate of TNFRSF14 gene alterations related to 1p36 region in de novo follicular lymphoma and impact on prognosis, Leukemia, 26, 559, 10.1038/leu.2011.266 Correia, 2015, BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma, Blood, 125, 658, 10.1182/blood-2014-04-571786 McCabe, 2013, EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations, Nature, 492, 108, 10.1038/nature11606 Béguelin, 2013, EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation, Cancer Cell, 23, 677, 10.1016/j.ccr.2013.04.011